Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

OBJECTIVES: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A (IL-17A), has shown significant efficacy in the treatment of psoriatic arthritis (PsA) and sustained long-term clinical response without unexpected new safety outcome for an IL-17A inhibitor. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul A, Combe, Bernard, Accioly, Ana P, Bolce, Rebecca, Zhu, Danting, Gellett, Amanda M, Sprabery, Aubrey Trevelin, Burmester, Gerd-Rüdiger R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209663/
https://www.ncbi.nlm.nih.gov/pubmed/35393269
http://dx.doi.org/10.1136/annrheumdis-2021-222027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209663/
https://www.ncbi.nlm.nih.gov/pubmed/35393269
http://dx.doi.org/10.1136/annrheumdis-2021-222027

Ejemplares similares